Novo Nordisk

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

Weight-loss drugs ‘will be a $60bn market in 10 years’

Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade,

News

UK plans $40m pilot of obesity drug Wegovy in primary care

Novo Nordisk’s obesity drug isn’t even available in the UK yet, but the government has already launched a pilot programme that could see access to the drug expanded throug

News

Novo Nordisk in talks to buy device maker Biocorp

Danish pharma group Novo Nordisk has revealed it is in exclusive negotiations that could result in the acquisition of a controlling stake in Biocorp, a French company that

News

ElevateBio cooks up $401m round, garnished with a Novo deal

Cell and gene therapy specialist ElevateBio has taken the total fundraising since it launched five years ago to around $1.25 billion, with its latest $401 million round th

News

Novo Nordisk says oral Wegovy hits weight loss goal

Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug W

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

Weight-loss drugs ‘will be a $60bn market in 10 years’

UK plans $40m pilot of obesity drug Wegovy in primary care

Novo Nordisk in talks to buy device maker Biocorp

ElevateBio cooks up $401m round, garnished with a Novo deal

Novo Nordisk says oral Wegovy hits weight loss goal

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks